Outlook Therapeutics, Inc.’s OTLK share price has dipped by 10.19%, which has investors questioning if this is right time to ...

OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United Kingdom (UK) for the first authorized use of an ophthalmic formulation of bevacizumab ...

On behalf of the Board of Directors, management, and employees of Outlook Therapeutics, I want to extend my deepest gratitude ...

Outlook Therapeutics OTLK reported preliminary top-line results from the 90-day non-inferiority NORSE EIGHT clinical study evaluating ONS-5010 (Lytenava) to treat patients with wet age-related ...

This feature is currently unavailable; we are sorry for the inconvenience to you. Nasdaq Analyst Research provides analyst research for ratings consensus and a summary of stock price targets ...

Short interest in Outlook Therapeutics Inc (NASDAQ:OTLK) decreased during the last reporting period, falling from 4.13M to 3.51M. This put 21.82% of the company's publicly available shares short.

ISELIN, N.J., Jan. 31, 2025 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union (EU) and the United ...

Outlook Therapeutics (OTLK) announced Faisal Sukhtian has been appointed as Chairman of the Board of Directors, effective immediately. Sukhtian ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Outlook Therapeutics, Inc. (OTLK) stock price is 2.06 and Outlook Therapeutics, Inc. (OTLK) 10-day simple moving average is 2.05. Outlook Therapeutics, Inc. (OTLK) stock price is 2.06 and Outlook ...